Building on the quality foundation of dual China-Europe GMP certification and the in-depth partnership with STADA from Germany for producing high-quality drug products, Kisun Pharm adhere to international standards, drive innovation in R&D, and advance a diverse product pipelines. We are committed to providing safer, more reliable, and more trustworthy pharmaceutical solutions for patients worldwide.

Zhejiang Kisun Pharmaceutical Co., Ltd., headquartered in Zhejiang with a global vision, is a modern pharmaceutical enterprise specializing in the R&D and production of high-quality drug products. Kisun's production facilities have obtained both Chinese and European GMP certifications, achieving full alignment with international standards through rigorous quality systems and standardized management. Through its deep collaboration with the renowned German pharmaceutical company STADA, Kisun jointly produces a range of high-end formulations, creating synergistic advantages in quality control, technical processes, and market expansion. Adhering to the philosophy of "Quality as the Foundation, Innovation-Driven, Patient-First," Kisun continuously increases its R&D investment. Kisun has built pipelines of multiple drug products under development with significant market potential and clinical value, addressing therapeutic needs across various fields. Committed to providing safer, more effective, and more stable drug products options to healthcare institutions and patients worldwide, Kisun strives to become a trustworthy international pharmaceutical partner.

The Imatinib Mesylate Tablets (Qi Ao Ning®) produced by Zhejiang Kisun Pharmaceutical Co., Ltd. have been approved for marketing in China by the National Medical Products Administration (NMPA). The product utilizes APIs supplied by STADA and is manufactured into tablets by Kisun. It shares the same production line as the homologous product supplied to the European market, maintaining consistent manufacturing processes and quality control systems. The overall standard of the product is on par with similar products available in Europe.

Drug products from the same production line have already been successfully listed in tenders and are being steadily supplied to multiple European countries, gaining recognition in the international market. This fully demonstrates Kisun's manufacturing strength and stable supply capability under a global quality system.

· Nationally Approved: Formally approved by China's National Medical Products Administration (NMPA) (National Drug Approval No. H20255339), compliantly marketed with transparent and traceable quality standards.
· International Standards: Supplies APIs to STADA Germany and produces tablets, guided by international collaboration, with integrated raw material and drug product processes ensuring stable quality and consistency.
Same Line, Standard, and Quality as Europe: Strictly adheres to EU GMP requirements, with key process parameters and quality control consistent with homologous European products.
· European Market Validated: Products from the same production line have been successfully listed in European tenders and maintain continuous supply, with quality proven through both clinical use and market acceptance.
· Stable & Accessible: Mature supply chain and comprehensive quality management ensure sustained and reliable market supply.

Guided by the principle of "Earning Trust through Quality, Safeguarding Health with Responsibility," Zhejiang Kisun Pharmaceutical Co., Ltd. remains committed to providing reliable, stable, and trustworthy drug products options for clinical use and patients, consistently adhering to international standards and a rigorous quality system.